Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Halcinonide is a corticosteroid used for the management and symptomatic relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Halcinonide is marketed under the brand name Halog® by Ranbaxy Laboratories Inc.
- Mechanism
- Curator reviewed
The precise mechanism of action of topical corticosteroids is unclear. However they possess anti-inflammatory, antipruritic, and vasoconstrictive actions.
New research indicates that halcinonide activates MBP (myelin basic protein) expression via smoothened receptor activation. This finding suggests that halcinonide could be used in the treatment of multiple sclerosis therapy as an alternative to Dexamethasone or Methylprednisolone.
- Primary indication
- Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.Curator reviewed · 3 structured indications
- Formula / weight
- C24H32ClFO5 · 454.96 g/mol (avg)
- First approval
- Canada, 2005 · United States, 2008
- Code names
- SQ-18566
- Brand names
- Halog
Resolves to
MUQNGPZZQDCDFT-JNQJZLCISA-NSMILES[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Halcinonide, and which of those have an active Phase 3 trial?